Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension

Trial Profile

Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Amyotrophic lateral sclerosis; Motor neuron disease
  • Focus Therapeutic Use
  • Acronyms LEVALS
  • Sponsors Orion
  • Most Recent Events

    • 26 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Orion media release.
    • 19 Sep 2017 Trial has been completed in Netherlands.
    • 04 Aug 2017 This trial has been completed in Ireland (end date: 11 May 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top